Emerging data suggest Retatrutide , a dual stimulator targeting both the gut-brain axis and GIP , could provide a significant step forward for weight loss . Initial patient investigations have indicated impressive losses in visceral tissue, potentially outperforming current weight-loss medications . Despite this, additional assessment is required t